$1.45
2.03% day before yesterday
Nasdaq, Sep 12, 10:00 pm CET

MaxCyte Inc Stock price

$1.45
+0.18 14.17% 1M
-1.73 54.40% 6M
-2.71 65.14% YTD
-2.55 63.75% 1Y
-5.06 77.73% 3Y
-0.18 11.04% 5Y
-0.14 8.99% 10Y
-0.14 8.99% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.03 2.03%

Key metrics

Basic
Market capitalization
$154.6m
Enterprise Value
$28.0m
Net debt
positive
Cash
$126.6m
Shares outstanding
106.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.3 | 4.2
EV/Sales
0.8 | 0.8
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
86.1%
Return on Equity
-19.9%
ROCE
-25.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$35.8m | $37.1m
EBITDA
$-49.3m | $-33.3m
EBIT
$-53.5m | $-55.1m
Net Income
$-44.8m | $-46.0m
Free Cash Flow
$-38.3m
Growth (TTM | estimate)
Revenue
-21.3% | -3.9%
EBITDA
-17.1% | 29.3%
EBIT
-15.5% | -7.6%
Net Income
-26.4% | -12.1%
Free Cash Flow
-50.8%
Margin (TTM | estimate)
Gross
79.8%
EBITDA
-137.9% | -89.6%
EBIT
-149.6%
Net
-125.2% | -124.0%
Free Cash Flow
-107.0%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
3.1%
Employees
114
Rev per Employee
$340.0k
Show more

Is MaxCyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

MaxCyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a MaxCyte Inc forecast:

10x Buy
77%
3x Hold
23%

Analyst Opinions

13 Analysts have issued a MaxCyte Inc forecast:

Buy
77%
Hold
23%

Financial data from MaxCyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
36 36
21% 21%
100%
- Direct Costs 7.23 7.23
38% 38%
20%
29 29
29% 29%
80%
- Selling and Administrative Expenses 55 55
5% 5%
153%
- Research and Development Expense 22 22
9% 9%
62%
-49 -49
17% 17%
-138%
- Depreciation and Amortization 4.18 4.18
0% 0%
12%
EBIT (Operating Income) EBIT -53 -53
16% 16%
-150%
Net Profit -45 -45
26% 26%
-125%

In millions USD.

Don't miss a Thing! We will send you all news about MaxCyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MaxCyte Inc Stock News

Neutral
Seeking Alpha
about one month ago
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Douglas J. Swirsky - Chief Financial Officer Maher Masoud - President, CEO & Executive Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Hannah Webb Hefley - Stephens Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.
Neutral
The Motley Fool
about one month ago
MaxCyte (MXCT) Q2 Revenue Drops 18%
Neutral
GlobeNewsWire
about one month ago
MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell therapy gene edited programs
More MaxCyte Inc News

Company Profile

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Maher Masoud
Employees 114
Founded 1998
Website www.maxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today